GRAFORCE
15.5.2023 02:01:27 CEST | Business Wire | Press release
Graforce, Germany’s leading provider of zero carbon hydrogen plants, and Worley, a leading global engineering and project delivery business, are cooperating to scale methane electrolysis (plasmalysis) starting in Australia, Pacific, Asia and China. Plasmalysis is a game changing technology, which converts natural gas, LNG, flare gas and other hydrocarbons into hydrogen without emitting CO2 or any other greenhouse gas into the atmosphere. This allows gas consumers to switch to clean-burning hydrogen without changing their energy supplier or mode of transportation. Graforce and Worley will present plasmalysis plants at APPEA 2023 in Adelaide, Australia (15-18 May) at the Worley sponsored Hydrogen Pavilion showcasing latest innovations in the hydrogen industry and its impact on decarbonization of industries and fossil fuels.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230514005004/en/
Methane Plasmalysis plants – graphics shows a 12 MW plant - convert natural gas, LNG, flare gas and other hydrocarbons into hydrogen without emitting carbon dioxide or any other greenhouse gas into the atmosphere. This allows gas consumers to switch to clean-burning hydrogen without changing their energy supplier or way of transportation. (Graphic: Business Wire)
Australia is among the largest producers of natural gas and one of the world's leading fuel suppliers. Projects to supply Germany with LNG and green hydrogen are in progress. At the same time, the country aims to reduce its CO2 emissions by more than 40 percent by 2030. Sustainable technologies like plasmalysis are an essential requirement to meet both, economic and climate targets.
“The entire APAC region is looking for green technologies for existing energy sources to achieve climate targets. The cooperation with Worley is an important step for us to quickly scale our methane plasmalysis and to open up these markets,” said Dr. Jens Hanke, CTO of Graforce.
Worley provides large scale engineering, procurement, and construction services to the energy, resources, and chemicals industries. Worley will provide engineering and project delivery services for plasmalysis plants customers in Australia and Asia. In the modular plants, a high-frequency plasma field generated by renewable electricity splits hydrocarbons such as methane into their molecular components: hydrogen and solid carbon. Compared to water electrolysis, plasmalysis requires only one-fifth the energy to produce the same amount of hydrogen. A single 20-megawatt plant can convert about 70,000 metric tons of methane into hydrogen per year and eliminate about 200,000 metric tons of CO2 emissions.
“As we scale up towards the vast quantities of renewable energy and hydrogen required to meet our Net Zero goals, our medium-term reliance on fossil fuels and in particular, natural gas and LNG, is a given. Plasmalysis marries these two realities together and enables faster decarbonisation utilising existing infrastructure. Plasmalysis is likely to be a valuable tool in the decarbonisation toolbox and contribute to our company purpose of delivering a more sustainable world,” says Gillian Cagney, Worley ANZ Managing Director.
About
Graforce is a German hydrogen technology company. Their power-to-X plants produce carbon dioxide free or carbon dioxide negative hydrogen and synthetic feedstocks – with highest efficiency and lower infrastructure costs in the multi-megawatt range. Thus, Graforce decarbonizes fossil energies, industries and the heat, transport and building sectors. Graforce is currently in the process of expanding its financial and strategic partnerships to quickly scale its hydrogen technology worldwide.
Worley is a global company headquartered in Australia and our purpose is delivering a more sustainable world. Worley is a leading global provider of professional project and asset services in the energy, chemicals and resources sectors. As a knowledge-based service provider, we use our knowledge and capabilities to support our customers to reduce their emissions and move towards a low carbon future. Worley Limited is listed on the Australian Securities Exchange (ASX: WOR).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230514005004/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom